BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34564882)

  • 21. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience.
    Shimazu Y; Notohara K; Ueda Y
    Int J Hematol; 2009 Jun; 89(5):577-83. PubMed ID: 19353238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
    Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [CNS involvement and the feasibility of intratecal chemotherapy administration in patients with a nodal form of diffuse large B-cell lymphoma not otherwise specified. Data of prospective study].
    Magomedova AU; Misyurina AE; Mangasarova JK; Gorenkova LG; Margolin OV; Fastova EA; Kravchenko SK
    Ter Arkh; 2019 Jul; 91(7):35-40. PubMed ID: 32598734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical analysis of patients with primary and secondary extranodal natural killer/T-cell lymphoma of central nervous system.
    Li X; Yu H; Fu X; Zhang L; Li X; Li L; Wang X; Sun Z; Zhang X; Li Z; Wu J; Chang Y; Yan J; Zhou Z; Nan F; Wu X; Tian L; Zhang M
    Hematol Oncol; 2023 Apr; 41(2):267-274. PubMed ID: 34061378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment strategy for central nervous system involvement in intravascular large B-cell lymphoma].
    Shimada K
    Brain Nerve; 2011 May; 63(5):467-72. PubMed ID: 21515926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era.
    Fletcher CD; Kahl BS
    Leuk Lymphoma; 2014 Oct; 55(10):2228-40. PubMed ID: 24286262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secondary central nervous system involvement in 599 patients with diffuse large B-cell lymphoma: are there any changes in the rituximab era?
    Deng L; Song Y; Zhu J; Zheng W; Wang X; Xie Y; Lin N; Tu M; Ping L; Ying Z; Liu W; Zhang C
    Int J Hematol; 2013 Dec; 98(6):664-71. PubMed ID: 24234713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
    Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
    Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review.
    Eyre TA; Djebbari F; Kirkwood AA; Collins GP
    Haematologica; 2020 Jul; 105(7):1914-1924. PubMed ID: 31488560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
    Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
    [No Abstract]   [Full Text] [Related]  

  • 31. The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis.
    Lin Z; Chen X; Liu L; Zeng H; Li Z; Xu B
    Crit Rev Oncol Hematol; 2022 Aug; 176():103756. PubMed ID: 35809794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients.
    Shimada K; Murase T; Matsue K; Okamoto M; Ichikawa N; Tsukamoto N; Niitsu N; Miwa H; Asaoku H; Kosugi H; Kikuchi A; Matsumoto M; Saburi Y; Masaki Y; Yamamoto K; Yamaguchi M; Nakamura S; Naoe T; Kinoshita T;
    Cancer Sci; 2010 Jun; 101(6):1480-6. PubMed ID: 20412122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical pathologic characteristics and treatment outcomes of 19 relapsed pediatric B-cell lymphoma].
    Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Ma XL; Zhang YH
    Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):748-753. PubMed ID: 29050112
    [No Abstract]   [Full Text] [Related]  

  • 34. Central nervous system involvement in T-cell lymphoma: A single center experience.
    Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
    Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extranodal site of diffuse large B-cell lymphoma and the risk of R-CHOP chemotherapy resistance and early relapse.
    Ting CY; Gan GG; Bee-Lan Ong D; Tan SY; Bee PC
    Int J Clin Pract; 2020 Oct; 74(10):e13594. PubMed ID: 32583545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical characteristics of 46 pediatric diffuse large B-cell lymphoma and treatment outcome].
    Huang S; Yang J; Jin L; Duan YL; Zhang M; Zhang NN; Li Q; Zhang N; Zhou CJ; Zhang YH
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):774-779. PubMed ID: 31594064
    [No Abstract]   [Full Text] [Related]  

  • 37. Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement.
    Lee KW; Yi J; Choi IS; Kim JH; Bang SM; Kim DW; Im SA; Kim TY; Yoon SS; Lee JS; Bang YJ; Park S; Kim BK; Cho HI; Heo DS
    Ann Hematol; 2009 Sep; 88(9):829-38. PubMed ID: 19172274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era.
    Zhang N; Xu D; Liu B; Shi X; Xie X; Wang Z
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109299. PubMed ID: 36252471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma.
    Gregory G; Arumugaswamy A; Leung T; Chan KL; Abikhair M; Tam C; Bajel A; Cher L; Grigg A; Ritchie D; Opat S
    Neuro Oncol; 2013 Aug; 15(8):1068-73. PubMed ID: 23502429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy.
    Al Feghali KA; Fang P; Gule-Monroe M; Milgrom S; Khoury JD; Gunther JR; Sheu T; Nair R; Ahmed S; Steiner R; Strati P; Shpall EJ; Nieto YL; Hosing C; Nastoupil LJ; Westin JR; Neelapu SS; Fowler N; Flowers C; Pinnix CC; Dabaja BS
    Leuk Lymphoma; 2021 Oct; 62(10):2400-2407. PubMed ID: 33942701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.